Catalyst Pharmaceutical Partners Announces Top-Line Results Of CPP-109 Phase II Trial For Cocaine Addiction

June 1, 2009

Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced top-line results from its U.S. Phase II clinical trial to treat cocaine addiction. The data from the trial showed that CPP-109 did not demonstrate statistical significance in the primary endpoint — that a significantly larger proportion of CPP-109-treated subjects than placebo-treated subjects were cocaine-free during the last two weeks of the treatment period (Weeks 11 and 12). The clinical trial did not reveal any unexpected “serious” adverse events.
Read the rest of this entry »

Advertisements

Cytori Completes Enrollment In First Adipose Stem & Regenerative Cell Therapy Trial For Chronic Heart Disease

May 30, 2009

Cytori (NASDAQ:CYTX) completed enrollment in the first study to investigate adipose derived stem and regenerative cells in chronic heart disease. The trial, which has been named the PRECISE study, was carried out at leading cardiology centers in Europe. It specifically enrolled patients suffering from an advanced form of chronic heart disease, known as chronic myocardial ischemia, for which there is no generally accepted treatment.

The trial enrolled 27 patients and was designed as a double-blind, randomized, placebo controlled, dose escalation study. It is unique in that the patients’ own cells were extracted from adipose tissue and processed for delivery at the point of care using Cytori’s Celution System. The cells were then injected back into the patients using the NOGA XP System (Biologics Delivery Systems, Cordis Corp., a Johnson and Johnson company), which identifies and guides cells to damaged regions of the heart.
Read the rest of this entry »


Zetiq Reports Success In Clinical Trial Aimed For Early Identification Of Cervical Cancer

May 28, 2009

Zetiq, a subsidiary of Bio-Light Ltd. (TASE:BOLT), reports the successful completion of a clinical trial to validate feasibility of early identification of cervical cancer.

The trial was conducted on cervical smears collected from 74 subjects at Meir MC and Macabbi health services in Israel. The collected samples were processed with the advanced liquid based cytology method, and examined using 3 methods: staining with the traditional widely used Pap method, testing to identify the presence of the HPV virus that causes the disease, and staining with the Zetiq method. The analysis of the specimens was conducted by the company’s team as well as by an independent professional.
Read the rest of this entry »


NEVO Sirolimus-Eluting Coronary Stent Yields Superior Results To Taxus(R) Liberte(R) Stent In Pivotal Clinical Trial

May 23, 2009

At six months, the NEVO™ Sirolimus-eluting Coronary Stent, incorporating RES Technology™, was superior to the Taxus Liberte Stent in reducing tissue growth within the stent that can potentially lead to repeat procedures, in new clinical study results released . In addition, no reports of stent thrombosis were reported in patients treated with NEVO™ through six months.

The results of the NEVO RES I study comparing these two drug-eluting stents were presented during Late Breaking Clinical Trials at EuroPCR, the leading medical conference in Europe for physicians specializing in interventional cardiovascular medicine.
Read the rest of this entry »


Trial Begins In Case Of Kansas Abortion Provider Tiller

March 27, 2009

Opening arguments began on Monday in the criminal case of Kansas abortion provider George Tiller, who is charged with 19 misdemeanor counts of failing to follow a Kansas law regarding later abortion, which requires approval of a second, independent doctor who practices in Kansas and has no financial or legal affiliations with the first doctor, according to the Los Angeles Times. “The doctor must certify that the mother will suffer permanent and irreversible harm, which can include psychological harm, if she carries the baby to term,” according to the Times.
Read the rest of this entry »


Clinical Trial Exploring Use Of Cardiac Device In New Groups Of Heart Failure Patients Completes Enrollment Phase

March 22, 2009

Medtronic, Inc. (NYSE: MDT) announces completion of the enrollment phase of 1,800 patients in the RAFT clinical trial (Resynchronization/Defibrillation for Ambulatory Heart Failure Trial), which is studying the impact of cardiac resynchronization therapy in mildly symptomatic heart failure patients, or those at risk of worsening heart failure, but not currently indicated under medical guidelines to receive treatment with the device.

“This study is important to guide therapy for heart failure patients with milder heart failure symptoms who have a dilated heart and poor heart function. These patients have a tendency to develop worsening symptoms, to require hospitalization, and they may die prematurely. This study will determine if cardiac resynchronization therapy, when used earlier in the disease, can delay or prevent the progression of heart failure,” said Anthony Tang, M.D., RAFT Nominated Principal Investigator and Adjunct Professor of Medicine, University of Ottawa.
Read the rest of this entry »


Scientists Trial Device To Treat Chemotherapy Related Nausea

March 21, 2009

Trials to test acupressure wrist bands as a drug-free alternative for chemotherapy-related nausea are to take place at the University of Liverpool.

More than 75% of patients undergoing chemotherapy experience nausea, which can impact negatively on their quality of life. Acupressure wrist bands can reduce the symptoms of travel sickness by applying force to the Nei Kuan pressure point on each wrist.

The national study of more than 700 patients, at nine NHS cancer centres, will now measure the cost and clinical effectiveness of acupressure wrist bands in reducing and controlling chemotherapy-related nausea. Led by Professor Mari Lloyd-Williams, from the University’s Academic Palliative and Supportive Care Studies Group, the team will analyse a wide range of patients, diagnosed with different types of cancer and undergoing chemotherapy, in order to discover which patient groups would most benefit from the intervention.
Read the rest of this entry »